24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
CARBOLIEVA 150MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | CARBOLIEVA 150MG |
|---|---|
| Composition | Carboplatin Injection IP 150mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
CARBOLIEVA 150MG (Carboplatin Injection IP 150mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
CARBOLIEVA 150 MG (Carboplatin Injection IP 150 mg) is a prescription anticancer medicine containing Carboplatin 150 mg, a platinum-based chemotherapy agent widely used in the treatment of various solid tumors. Carboplatin belongs to the class of Platinum Coordination Compounds, which work by interfering with the DNA of cancer cells, preventing their growth, multiplication, and spread.
Carboplatin is a well-established chemotherapy medicine used in modern oncology for its effectiveness against multiple cancer types and its predictable safety profile. The medicine forms cross-links within cancer cell DNA, disrupting DNA replication and cellular function, ultimately leading to cancer cell death.
CARBOLIEVA 150 MG is commonly prescribed either as a single-agent therapy or as part of combination chemotherapy regimens for cancers such as ovarian cancer, lung cancer, breast cancer, cervical cancer, and other advanced solid tumors.
The 150 mg strength provides flexibility in chemotherapy dosing and allows oncologists to tailor treatment according to the patient’s body surface area (BSA), kidney function, and treatment protocol.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
CARBOLIEVA 150 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, CARBOLIEVA 150 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Carboplatin therapy require routine monitoring of blood counts, kidney function, liver function, and overall health status to support safe and effective treatment.
Due to its established efficacy across multiple cancer indications, CARBOLIEVA 150 MG remains an important medicine in modern cancer care.
CARBOLIEVA 150 MG (Carboplatin Injection IP 150 mg) is primarily used in the treatment and management of various cancers.
Carboplatin is one of the most commonly prescribed chemotherapy medicines for ovarian cancer treatment.
The medicine is used in both non-small cell and small cell lung cancer treatment protocols.
Doctors may include Carboplatin in selected breast cancer treatment regimens.
The medicine may be prescribed in advanced or recurrent cervical cancer treatment plans.
Carboplatin is often used as part of combination chemotherapy programs.
The medicine may be incorporated into established treatment protocols for germ cell tumors.
Carboplatin is widely used in oncology treatment regimens for various advanced cancers.
Carboplatin belongs to a class of medicines known as Platinum-Based Anticancer Agents.
CARBOLIEVA works by:
This mechanism helps control cancer development and supports effective disease management.
Like all medicines, CARBOLIEVA 150 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
The medicine may reduce white blood cells, red blood cells, and platelet counts.
Digestive discomfort may occur during treatment.
Weakness and tiredness are commonly reported.
Some patients may experience reduced appetite.
Lower white blood cell counts may increase susceptibility to infections.
Reduced platelet counts may increase bleeding tendencies.
Changes in blood electrolyte levels may occur.
Regular monitoring is recommended throughout treatment.
Patients may experience reduced energy levels during therapy.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of CARBOLIEVA 150 MG (Carboplatin Injection IP 150 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the disease being treated.
Dosage calculations are commonly based on body surface area.
Renal function is an important factor when determining Carboplatin dosage.
Laboratory monitoring helps guide treatment decisions.
Concurrent anticancer medicines may influence dosing schedules.
Before starting treatment, inform your doctor if you have:
Patients receiving Carboplatin therapy may require:
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of ovarian cancer, lung cancer, breast cancer, cervical cancer, head and neck cancer, and other solid tumors.
Carboplatin is a platinum-based chemotherapy medicine that damages cancer cell DNA and prevents tumor growth.
Yes. Carboplatin is a widely used platinum-based chemotherapy agent.
Yes. It may reduce white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Kidney function monitoring is recommended during treatment.
Yes. Blood counts, kidney function, and clinical assessments are important throughout treatment.
Yes. It is frequently used alongside other anticancer medicines in established treatment protocols.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.